The Philadelphia (Ph) chromosome, resulting from the t(9;22) translocation, is characteristic of chronic myeloid leukemia (CML). As a result of this translocation, two novel chimeric genes are generated and the bcr/abl and abl/bcr fusion proteins expressed. The bcr/abl fusion mRNA is present in all CML patients, whereas the reciprocal abl/bcr fusion mRNA is detectable in about 80% of the Ph + CML patients. These fusion proteins may undergo enzymatic degradation in the cytosol and give rise to MHC class I restricted peptide epitopes originating from the junctional regions of the translocation products, which thus may serve as novel tumor specific antigens. Previously, other groups have tested peptides corresponding to the junctional region of the bcr/abl protein for their binding capacity to HLA class I molecules and have identified a few candidate epitopes. Peptides originating from the abl/bcr fusion protein have on the other hand so far been neglected, for no apparent reason. We have now extended these studies to include also the reciprocal abl/bcr translocation product by testing a large panel of synthetic peptides corresponding to the junctional regions of both the abl/bcr and the bcr/abl fusion proteins for their ability to stabilize HLA class I molecules. We find that the abl/bcr translocation product may be an even more important source of CML specific peptide antigens and together the junctional sequences of both these proteins contain peptide sequences which bind efficiently to a number of HLA molecules (HLA-A1, -A2, -A3, -A11, -B7, -B27, -B35) and thus may serve as candidate CML specific tumor antigens. Leukemia (2000) 14, 419-426.
Introduction
A large number of human cancers, including leukemias, lymphomas, and certain solid tumors are associated with chromosomal translocations resulting in the expression of novel fusion proteins. As a consequence of the t(9;22) translocation (Philadelphia chromosome) associated with chronic myeloid leukemia (CML) and around 20% of adult acute lymphoblastic leukemia (ALL), the c-abl proto-oncogene becomes activated by translocation to chromosome 22, and the novel chimeric gene is translated into a 210 kDa (p210) bcr/abl fusion protein. [1] [2] [3] [4] [5] The p210 protein is a potent tyrosine kinase with a transforming capacity which plays a key role in the pathogenesis of CML. 6, 7 Concurrently, the reciprocal translocation gives rise to the fusion protein abl/bcr. 8 Although the abl/bcr gene has indeed been shown to be transcribed in Ph + CML patients, its role in the pathogenesis of CML is not clear. 9 Furthermore, the potential role of abl/bcr fusion proteins has so far been neglected in immunological studies of CML. The first two authors contributed equally to this work Received 10 September 1999; accepted 15 November 1999 All the different fusion genes are in frame and depending on which exons of bcr and abl are spliced together in the final fusion mRNA, the junctional regions of the fusion proteins show some variation ( Figure 1) . Thus, the bcr/abl fusion protein is either of the b2a2 or the b3a2 type depending on whether the b2 or the b3 exon of bcr is spliced on to the a2 exon of abl. Similarly, the abl/bcr protein sequences are either of the aIab4, aIab3, aIbb4, or aIbb3 type depending on whether the ala or alb exons of abl are transcribed (these two exons have independent promoters) and on whether they are joined with the b3 or b4 exon of bcr.
The proteolytic degradation of translocation products in the cytosol may give rise to peptide fragments of novel sequence spanning the junctional region of the fusion proteins. These peptides may bind to class I MHC molecules for subsequent presentation as novel tumor antigens at the cell surface and recognition by cytotoxic T-lymphocytes (CTL). The objective of the present study was to identify potential tumor specific peptide antigens spanning the junctional sequence of either the bcr/abl or the abl/bcr translocation products. As a conse-
Figure 1
The examined bcr/abl and abl/bcr junctional sequences. 1, 7 The junctional amino acid are marked in bold (upper half of the figure). Schematic representation of the abl and the bcr genes (lower half of the figure). Exons are represented by boxes and introns by connecting horizontal lines. Breakpoint regions in abl and bcr are marked. The major bcr/abl fusion proteins are either of the b2a2 or the b3a2 type depending on whether the b2 or the b3 exon of bcr is spliced on to the a2 exon of abl. Similarly, the abl/bcr protein sequences are either of the aIab4, aIab3, aIbb4, or aIbb3 type depending on whether the ala or alb exons of abl are transcribed (these two exons have independent promoters) and on whether they are joined with the b3 or b4 exon of bcr.
quence of the breakpoint variation mentioned above, each of the possible fusion proteins possesses unique amino acid sequences across the junction (Figure 1 ). These junctional regions were screened for potential class I MHC peptide binding motifs for HLA-A1, -A2, -A3, -A11, -B7, -B27, -B35 and  -B51 molecules. 10 Out of the peptides identified, several peptides from both the bcr/abl or the abl/bcr fusion proteins displayed binding activity to at least one of the tested alleles.
Following the identification of HLA class I binding peptides the best binders were tested in an ELISPOT assay for ␥-interferon (IFN␥) release by peptide-specific CTL in order to examine whether bcr/abl or abl/bcr peptide-specific T cell precursors are present among peripheral blood mononuclear cells (PBMC) of CML patients.
Materials and methods

Peptide epitope prediction
Peptides which contained HLA class I peptide binding motifs were selected from the published bcr/abl 1 and abl/bcr 8 junctional sequences. 11 The different bcr/abl and abl/bcr junctional sequences are depicted in Figure 1 . Only primary anchor residues were considered, when selecting peptides containing potential peptide binding motifs, most often at position 2 and at the C-terminus. Furthermore, fairly degenerate motifs were allowed and less promising candidates were also included. Some peptides selected only contained one of the canonical anchor residues, and 10-mers and 11-mers were also accepted for some alleles. The positive or negative effects on binding exerted by so-called secondary anchor residues were not taken into consideration. All 9-mer and 10-mer peptides were also analyzed in the predictive algorithm designed by Dr K Parker, available at http://bimas.dcrt.nih.gov/molbio/ hla-bind. 12 For a list of the peptides, see Table 1 . Peptides used as positive controls in the assembly assay and in the ELIS-POT assay are listed in Table 2 . All synthetic peptides were purchased from Research Genetics (Huntsville, AL, USA) and provided at Ͼ90% purity as verified by HPLC and MS analysis.
Cell lines
The human T2 cell line is a TAP1 and TAP2 defective hybrid of the B-LCL.174 and the T-LCL CEM cells and thus only express low levels of HLA class I molecules (HLA-A*0201, HLA-B*5101) at the cell surface. 27 T2 cells transfected with a number of different HLA alleles were kindly provided by Dr A McMichael, IMM, John Radcliffe Hospital, Oxford, UK (HLA-A*0301, -B*0702, -B*2705, -B*3501), and Dr M Masucci, MTC, Karolinska Institute, Stockholm, Sweden (HLA-A*1101). [28] [29] [30] [31] [32] [33] The BM36.1 cell line is also defective in TAP function and has a similar phenotype as T2 with low expression of HLA class I (HLA-A*0101, HLA-B*3501) at the surface. 34 BM36.1 cells were kindly provided by Dr A Ziegler, Humboldt University, Berlin, Germany.
An EBV-transformed B-lymphoblastoid cell line was established from the donor KIG expressing HLA-A2, -A3, -B7, and -B15 by co-culturing PBMC with supernatant from the EBV-infected marmoset cell line B95.8 in the presence of cyclosporin A. 
Assembly assay for peptide binding to HLA class I molecules
The assembly assay was performed as described previously. 35, 36 Briefly, 5 × 10 6 T2 cells per experimental point were washed in warm PBS (37°C). Cells were resuspended in warm (37°C) methionine/cysteine free RPMI supplemented with 10% FCS (the FCS was dialysed against PBS prior to use) and 10 mM HEPES (Met/Cys free R10) at 10 7 cells/ml and incubated at 37°C, 5% CO 2 for 30-45 min. Cells were centrifuged and resuspended in Met/Cys free R10 at 10 8 cells per ml and 35 S-methionine/ 35 S-cysteine (Amersham Life Science) was added at 100 Ci per 10 7 cells and incubated at 37°C, 5% CO 2 for 20-30 min. Cells were washed in cold PBS (1×) and aliquots of 5 × 10 6 cells were lysed in 0.5 ml lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 0.5% NP-40 (Fluka, Buchs, Switzerland), 3 mM EDTA, pH 7.5) in the presence of protease inhibitors (2 mM PMSF (Sigma), 5 mM iodoacetamide (Sigma), 2 g/ml pepstatin A (Sigma), 2 g/ml leupeptin (Sigma)) with or without synthetic peptide at a final concentration of 20 mM, 2 mM, 0.2 mM and incubated on ice for 30 min. Subsequently, nuclei were pelleted (13 000 g, 5 min) and the supernatants transferred into clean tubes and incubated on ice for 90 min. A heating step was then included for the supernatant of T2-A3 (45°C 5 min), T2-A11 (55°C 5 min), or T2-B27 (55°C 5 min) in order to reduce background signals by preferentially destabilizing empty HLA-A3, -A11, or -B27. 36 Thereafter samples were quickly returned to ice. Staphylococcus aureus (Pansorbin; Calbiochem, Nottingham, UK) freshly washed in lysis buffer (3×) was added to the supernatants (50 l, 10% v/v) in order to pre-clear the samples for protein A-binding molecules while incubating at 4°C overnight (rotating). The following day pansorbin was pelleted, and the supernatants transferred into clean tubes, before addition of the appropriate monoclonal antibody at a final concentration of 10 g/ml, and incubation on ice (90 min). Then, 50 l (10% v/v) of Protein A-Sepharose beads (Sigma) were added to the samples and incubated 60 min at 4°C rotating. The beads were washed (3×) in lysis buffer. The samples were eluted from the beads by incubating in loading buffer for 30 min at RT and run on a polyacrylamide isoelectric focusing gel modified from Neefjes et al, 37 as described previously. 36 A 5% polyacrylamide gel (Accugel 19:1, National Diagnostics, Atlanta, GA, USA) was prepared with 25 mg/ml ampholine pH 5-7 and 8.4 mg/ml ampholine pH 3.5-9 (Pharmacia Biotech, Freiburg, Germany). The gel was run at the following limits: 880 V, 12 mA, 8 W for 16 h. The amount of 35 S-labelled, immunoprecipitated HLA heavy chain bands were quantified using the Imagequant Phosphorimager program (Molecular Dynamics, Sunnyvale, CA, USA). The intensity of the band is directly related to the amount of peptide-bound class I HLA complex recovered in the assay.
Antibodies
The HLA class I specific monoclonal antibody (mAb) W6/32 was used for the immunoprecipitation in most assays, 38 except for the immunoprecipitation of HLA-A2 molecules, where the mAb BB7.2 was used. 39 
CML patient material
PBMC from four chronic phase CML patients were separated from heparinized whole blood using the standard Lymphoprep protocol. Patient 1 received ␣-interferon and hydroxyurea, patient 2 received ␣-interferon, patient 3 received hydroxyurea, and patient 4 was untreated. Serological HLA typing was performed at the National Blood Bank of Denmark, Aarhus. The patients carried the following HLA class I types: CML patient 1: HLA-A1, -A2, -B27, -B44; CML patient 2: HLA-A2, -A11, -B15, -B16; CML patient 3: HLA-A2, -A26, -B8, -B14; CML patient 4: HLA-A2, -A19, -B13, -B62.
Leukemia
ELISPOT assay for CTL precursors reactive with HLA class I binding peptides
The ELISPOT protocol was adapted from Lalvani et al, 40 and Scheibenbogen et al. 41 Nitrocellulose bottomed 96-well plates (MultiScreen MAIP N45, Millipore, Hedehusene, Denmark) were coated overnight at 4°C with 7.5 g/ml of anti-IFN-␥ antibody (1-D1K, Mabtech, Nacka, Sweden) in 75 l sterile PBS and the wells were washed (6×) with PBS. Non-specific binding was blocked by incubating with 200 l/well R10 (RPMI with 10% FCS) for 2 h at 37°C. Freshly isolated PBMC were added at 10 6 cells per well in 100 l R10 in triplicates. Peptides were added to cells to a final concentration of 2 M and incubated overnight at 37°C with 5% CO 2 . The next day the wells were emptied and washed with PBS containing 0.05% Tween (PBS/Tw) (6×) before the addition of biotinylated secondary antibody (7-B6-1-Biotin, Mabtech) at 0.5 g/ml in 75 l PBS containing 1% BSA and 0.02% NaN 3 (PBS/BSA) and incubation at room temperature (RT) for 3 h. The wells were washed (6×) with PBS/Tw. Then 75 l of avidin-enzyme conjugate (AP-Avidin, Calbiochem) diluted 1:2000 in PBS/BSA was added to each well and incubated at RT for 1 h. Meanwhile the enzyme substrate NBT/BCIP was prepared according to the manufacturers' instructions (Gibco, code 18280-016) and 75 l of the substrate was added to each well and incubated at RT for 10-20 min. The reaction was stopped by washing with tap water upon the emergence of dark purple spots. The spots were counted using a Leica Zoom 2000 microscope and the CTLp frequency was calculated as the number of spot-forming cells (SFC) per 10 6 of PBMC added per well.
Generation of CTL lines
Peptide-specific CTL were established in vitro as primary responses from healthy human donors using autologous dendritic cells (DC) as antigen presenting cells, as described previously. 42 Briefly, DC were generated from PBMC by culturing 10 days in the presence of GM-CSF (Leucomax, Sandoz, Germany) and IL-4 (PeproTec, Boston, MA, USA). The DC were then incubated with peptide, irradiated, and co-cultured with fresh, autologous PBMC in the presence of IL-7 (PeproTech). On day 10, and weekly thereafter, the resulting CTL lines were restimulated with peptide-pulsed autologous PBMC, and addition of IL-2 (PeproTech) on the following day.
CTL cytotoxicity assay
The peptide specificity of CTL lines were tested in conventional 51 Cr release assays for CTL-mediated cytotoxicity against peptide-pulsed target cells. Briefly, autologous EBVtransformed B cell lines were labelled with 51 Cr in the presence of peptide before addition to CTL at various effector/target ratios. After 4 h at 37°C, release of 51 Cr from target cells was measured by counting of media in a Gammacounter (Cobra 5005, Packard Instruments, Meriden, CN, USA) and specific lysis calculated using the following formula ((experimental release − spontaneous release)/(maximum release − spontaneous release)) × 100.
Results
Results of peptide predictions
Twenty-eight peptides from the different bcr/abl (b2a2,b3a2) and abl/bcr (aIab3, aIab4, aIbb3, aIbb4) junctional sequences were selected which contained classical or degenerate peptide binding motifs for different HLA class I molecules: HLA-A1, -A2, -A3, -A11, -B7, -B27, -B35, -B51. 11 Only primary anchor residues were considered and peptides of 9, 10, or 11 amino acid length were included. The result of the predictions are summarized in Table 1 .
Binding of bcr/abl and abl/bcr peptides to different HLA class I molecules
The 28 selected peptides were tested for their ability to stabilize HLA class I molecules in the assembly assay, as compared with a panel of positive control peptides (see Table 2 ). Peptides selected carrying a peptide binding motif for one HLA allele, were also tested for binding to all the remaining class I HLA alleles examined in the present study. Representative results of peptide binding assays for HLA-A1, -A2, -A3, and -B35 are shown in Figure 2 . The results of the binding assays are summarized in Table 3 .
Figure 2
Peptide binding to HLA-A1, HLA-A2, HLA-A3, and HLA-B35 (panels a to d, respectively). The binding of the positive control peptide C1 was compared with the three abl/bcr peptides a13 (EHDDESPGLY), a16 (VEHDLYCTL), and a12 (HDDESPGLY) (a). The binding of the positive control peptide C20 was compared with the three abl/bcr peptides a9 (YLEDLYCTL), a14 (FVEHDDESPGL), and a18 (NVFVEHDLY), and the bcr/abl peptide b8 (PLTINKEEAL) (b). The binding of the positive control peptide C22 was compared with the abl/bcr peptide al (EDDESPGLY), and the two bcr/abl peptides b5 (KQSSKALQR) and b6 (FKQSSKALQR) (c). The binding of the positive control peptide C19 was compared with the two abl/bcr peptides a5 (SSCYLEDLY) and a18 (NVFVEHDLY), and the bcr/abl peptide b6 (FKQSSKALQR) (d).
Table 3
Binding of bcr/abl peptides to HLA class I molecules
−, no binding; +, weak binding; +++, strong binding; nt, not tested.
Strong binding was defined as when the amount of HLA class I molecules stabilized constituted at least 70% of the amount stabilized by the control peptide at the two highest peptide concentrations (20 M and 2 M). Weak binding was defined as when the amount of HLA class I molecules stabilized by the peptide tested was between 35-70% of that of the control peptide at the two highest peptide concentrations (20 M and 2 M) (Figure 2 
bcr/abl peptides
Among the peptides from the b3a2 bcr/abl fusion protein two peptides were identified (b5, b6) which showed weak binding to HLA-A3 and three peptides (b4, b5, b6) bound weakly to HLA-A11 (Figure 2c , Table 3 ). One peptide (b4) bound strongly to HLA-B7 (Table 3) . Of the b2a2 peptides b7 and b9 showed strong binding to HLA-A2 and HLA-B35, respectively ( Figure 2a , Table 3 ). Three b2a2 peptides b7, b8, b9 bound strongly to HLA-B7 (Table 3) .
abl/bcr peptides
Among the four types of abl/bcr junctional peptides, several showed strong binding to HLA-A1 and -A2 (Table 4 , Figure 3 ). For HLA-A1 the following peptides were strong binders: the aIab3 peptides a2 and a3, the aIab4 peptides a5, a6, a7, a8, and a9, and the aIbb3 peptides a12 and a13. For HLA-A2 the following peptides were strong binders: the alab3 peptide a4, the aIab4 peptides a9 and a10, the albb3 peptide a14 and the aIbb4 peptide a17. Weak binders for HLA-A2 were the aIab4 peptide a8 and the aIbb4 peptide a15. Two aIab4 peptides (a5, a6) and one aIbb4 peptide (a18) bound strongly and one aIbb3 peptide (a14) weakly to HLA-B35 (Table 4) . None of the abl/bcr peptides showed detectable binding to HLA-A3, -A11, or -B7 molecules (Table 4) .
ELISPOT assay for CTL precursors reactive with HLA class I binding peptides
All four CML patients were HLA-A2 positive. PBMC from all CML patients were tested for the presence of CTL precursors Table 4 Binding of abl/bcr peptides to HLA class I molecules
Figure 3
A CTL line generated from the HLA-A*0201 positive healthy human donor KIG was tested in a conventional 51 Cr release assay for CTL-mediated cytotoxicity against target cells pulsed with the HLA-A*0201-binding abl/bcr-derived peptide a9 (dark circle) or an irrelevant HLA-A*0201-binding control peptide (white circle).
(CTLp) specific for the strong HLA-A2 binding peptides b7, a4, a9, a10, a14, a17, and the weak binding peptides: a8, a15. In addition, patient CML 1 was HLA-A1 positive and was tested for the HLA-A1 binding peptides a2, a3, a5, a6, a7, a8, a9, a12, a13. Patient CML 2 was HLA-A11 positive and was tested for the three weak HLA-A11 binding peptides b4, b5, b6. However, none of the four CML patients possessed detectable CTLp for any of the peptides tested with a threshold of detection at 10-100 SCF per 10 6 . The influenza virus and EBV positive control peptides are listed in Table 2 . Significant CTLp frequencies against these control peptides were detectable in PBMC from all four CML patients (data not shown).
HLA-A*0201 restricted human CTL specific for an abl/bcr peptide
Having confirmed the efficient binding to HLA-A*0201 (Figure 2b) , the abl/bcr-derived peptide a9 peptide was used to generate human in vitro primary CTL responses using a HLA-A*0201-positive, healthy donor. Autologous DC generated from PBMC in the presence of IL-4 and GM-CSF and pulsed with peptide a9 were used to stimulate CTL in vitro in the presence of IL-2 and IL-7. After 5 weeks of restimulation, the peptide specificity was tested in a standard 51 Cr release assay using peptide-pulsed autologous EBV-transformed B cells as target cells. Only target cells pulsed with peptide a9 were lysed (Figure 3a) . These results clearly demonstrate the ability to generate peptide-specific class I MHC-restricted CTL against peptides spanning the junctional region of the abl/bcr protein.
Discussion
The present study was aimed at identifying peptides corresponding to the junctional regions of the bcr/abl and abl/bcr fusion proteins that could stabilize HLA class I molecules and serve as potential CML specific tumor antigens. A panel of 28 synthetic 9-, 10-, or 11-mer peptides were tested in a binding assay. Subsequently, the potential immunological relevance of the peptides was assessed by measuring peptide-specific CTL precursor frequencies in PBMC of CML patients.
We found that two bcr/abl b3a2 peptides (b5 and b6) bound weakly to HLA-A3 and -A11 in the assembly assay. The peptide b5 has previously been described as a strong HLA-A3 binder and an intermediate -A11 binder using a standard inhibition assay for peptide binding or a HLA class I ␣-chain stabilization assay. [43] [44] [45] The b6 peptide has been described as an intermediate binder for HLA-A3 and a weak binder for -A11. 43 Although the results converge in that both these peptides are able to bind HLA-A3 and -A11, the discrepancy with regards to the affinity of binding most likely depends on the assays used. We also find that the b2a2 peptide b7 stabilizes HLA-A2 and that the peptide b9 is a strong binder to HLA-B7 in the assembly assay. These results disagree with earlier publications concerning these two peptides, as previous studies did not report any binding in the peptide inhibition assay. 43 The b9 peptide, although an 11-mer, contains the optimal anchor residues for HLA-B7, namely a P at position 2 and L at the C-terminus. Furthermore, b9 also binds strongly to HLA-B35 (Table 3 ), in agreement with the presence of a classical HLA-B35 binding motif (P at position 2 and L at the C-terminus). Our observations agree with earlier publications concerning the two b3a2 peptides b2, b4, and the b2a2 peptide b8, as these do not bind to HLA-A1 or -A2. [45] [46] [47] Here we also report that the abl/bcr fusion proteins resulting from the reciprocal translocation in Ph + CML may serve as an important source of CML specific peptide epitopes presented by HLA class I molecules. Thus, a significant number of abl/bcr peptides display strong binding to HLA-A1, -A2, -B27, and -B35. Some of these peptides contain the optimal binding motif for HLA-A1 (E or D at position 3 and Y or L at the Cterminus): a2, a3, a9, a12, a13 (Table 1) . Interestingly, S or C at position 3 seems to be able to replace D or E whilst still ensuring strong binding (peptides a5, a6, a7, a8) (Tables 1 and  4) . No binding was observed for the peptide a1, in spite of the presence of a promising HLA-A1 binding motif. Some of the peptides carrying HLA-A2 binding motifs also bound strongly to HLA-A2, eg a4, a10, a14, a17 (Tables 1 and 4 ). These are 10-mer or 11-mer peptides, thus longer than the majority of HLA-A2 binding 9-mers. 11 Three abl/bcr peptides showed high affinity binding to HLA-B35 (peptides a5, a6, a18), all containing a partial binding motif for HLA-B35 with Tyr at the C-terminus.
We have furthermore shown that an abl/bcr-derived junctional region peptide binding to HLA-A*0201 can elicit a peptide-specific, HLA-A*0201-restricted CTL response from normal human PBMC. In future studies we will attempt to address whether class I MHC-restricted T cell responses against endogenously presented peptides from the fusion region of either abl/bcr or bcr/abl are part of the natural T cell repertoire in individuals carrying the t(9;22) Philadelphia chromosome.
In summary, our study further supports the notion that the bcr/abl fusion protein is a good candidate source of tumor specific antigens in CML. Furthermore, we find that the abl/bcr fusion protein may be an even more important source of MHC class I-restricted peptide antigens in CML, and that such peptides could potentially be used as immunogens for the generation of CML specific immune responses.
Once potential CML specific peptide antigens have been identified, these could be used either as immunogens to gen- Cr-release assay. 48 CTL which recognised b2a2 or b3a3 bcr/abl peptides on syngeneic antigen presenting cells (APC) or leukemia, t(9;22) positive dendritic cells have also been generated. 45, 49, 50 Most recently, HLA-A2.1 restricted CTL specific for the SSKALQRPV bcr/abl peptide (not included in the present study) were generated which could kill autologous CML tumour cells. 51 Also HLA class II has been implicated in CML-specific immune responses. Bcr/abl peptides were shown to bind HLA-DR molecules and evoke T cell responses, as measured by IFN␥ and TNF␣ production, 52,53 CD4 + T cell lines could also be generated which recognised an 11-mer bcr/abl peptide of b3a2. 44, 54 Furthermore, a proliferative response of PBMC from CML patients could be generated when stimulated with a lysate of bcr/abl expressing cells. 55 Allogeneic stem cell transplantation (SCT) so far is the only curative treatment of CML, and this effect is supposed at least in part to be immunologically mediated. 56 Furthermore, infusion of donor T cell following SCT results in complete remission in a large proportion of patients. 57, 58 In another recent study, donor-derived bcr-abl specific CTL were generated by stimulation with dendritic cells pulsed with a 12-amino acid long peptide derived from bcr-abl. 59 These results suggest that immunological intervention in the form of immunization or adoptive immunotherapy may result in a more efficient treatment of CML. 60 However, there is still only limited support to the notion that Ph + -derived peptides may be employed to stimulate clinically beneficent immune responses in CML patients. In this study we have provided important additional data on the ability of bcr/abl, as well as abl/bcr derived peptides to bind to a range of common HLA class I molecules and these peptides are good candidates for such trials.
Before the planning of eventual adoptive immunotherapeutic strategies for CML it is important to address the question whether CTL recognising CML specific antigens are present in the blood of CML patients and whether this could be correlated to clinical relevance. Therefore, we tested PBMC from four CML patients in an ELISPOT assay in order to estimate the CTLp frequencies against candidate bcr/abl and abl/bcr peptide epitopes. Using this assay we could not detect any CTLp recognising bcr/abl and abl/bcr junctional peptides. However, due to a very high background formation of spots without peptide added, the sensitivity of our ELISPOT assay on PBMC from CML patients was reduced as compared to PBMC from normal controls when testing normal recall antigens, such as influenza virus and EBV antigens. The high background was found in all experiments, consistent with a poor quality of the PBMC from CML patients. As a result of this, the detection limit of our assay was 10-100 specific CTLp in 10 6 PBMC. Thus, if bcr/abl or abl/bcr peptide-specific CTLp were present in the peripheral blood of CML patients at a lower frequency we would not detect those in this assay. Although EBV and influenza specific CTLp could be detected with the ELISPOT assay in contrast to bcr/abl and abl/bcr peptides, these results do not formally exclude the possibility that CTLp against bcr/abl or abl/bcr specific antigens are present at a low level in the blood of CML patients.
